Axa’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.64M Sell
1,780
-945
-35% -$958K 0.64% 21
2025
Q4
$2.93M Sell
2,725
-455
-14% -$435K 1.39% 18
2025
Q3
$2.43M Sell
3,180
-280,637
-99% -$209M 1.22% 17
2025
Q2
$221M Sell
283,817
-58,205
-17% -$45.2M 0.64% 27
2025
Q1
$282M Sell
342,022
-738
-0.2% -$614K 0.93% 15
2024
Q4
$265M Sell
342,760
-42,465
-11% -$35.2M 0.8% 19
2024
Q3
$341M Buy
385,225
+3,626
+1% +$3.26M 1.01% 14
2024
Q2
$345M Buy
381,599
+27,154
+8% +$21.7M 1.03% 14
2024
Q1
$276M Sell
354,445
-8,700
-2% -$6.19M 0.83% 21
2023
Q4
$212M Sell
363,145
-110,855
-23% -$64.7M 0.68% 25
2023
Q3
$255M Buy
474,000
+113,247
+31% +$58.4M 0.89% 16
2023
Q2
$169M Sell
360,753
-16,722
-4% -$7.01M 0.56% 32
2023
Q1
$130M Sell
377,475
-75,577
-17% -$25.5M 0.45% 43
2022
Q4
$166M Sell
453,052
-8,529
-2% -$3.02M 0.6% 28
2022
Q3
$149M Buy
461,581
+1,676
+0.4% +$531K 0.59% 25
2022
Q2
$149M Buy
459,905
+61,996
+16% +$18.6M 0.55% 31
2022
Q1
$114M Buy
397,909
+50,921
+15% +$13.1M 0.32% 74
2021
Q4
$95.8M Sell
346,988
-1,690
-0.5% -$428K 0.25% 103
2021
Q3
$80.6M Sell
348,678
-10,658
-3% -$2.63M 0.23% 102
2021
Q2
$82.5M Sell
359,336
-69,715
-16% -$14M 0.23% 101
2021
Q1
$80.2M Sell
429,051
-65,593
-13% -$12.8M 0.24% 97
2020
Q4
$83.5M Sell
494,644
-50,772
-9% -$7.58M 0.26% 91
2020
Q3
$80.7M Buy
545,416
+18,904
+4% +$2.93M 0.29% 76
2020
Q2
$86.4M Sell
526,512
-102,759
-16% -$15.8M 0.34% 63
2020
Q1
$87.3M Sell
629,271
-8,533
-1% -$1.17M 0.44% 50
2019
Q4
$83.8M Buy
637,804
+7,106
+1% +$824K 0.34% 66
2019
Q3
$70.5M Sell
630,698
-30,584
-5% -$3.41M 0.28% 89
2019
Q2
$73.3M Buy
661,282
+19,637
+3% +$2.31M 0.29% 88
2019
Q1
$83.3M Sell
641,645
-70,693
-10% -$8.6M 0.33% 74
2018
Q4
$82.4M Sell
712,338
-96,057
-12% -$10.7M 0.36% 70
2018
Q3
$86.7M Sell
808,395
-110,293
-12% -$11M 0.32% 77
2018
Q2
$78.4M Sell
918,688
-204,707
-18% -$16.8M 0.3% 87
2018
Q1
$86.9M Buy
1,123,395
+360,155
+47% +$29M 0.35% 74
2017
Q4
$64.5M Sell
763,240
-39,059
-5% -$3.32M 0.25% 108
2017
Q3
$68.6M Sell
802,299
-28,095
-3% -$2.3M 0.3% 89
2017
Q2
$68.3M Sell
830,394
-36,012
-4% -$2.94M 0.31% 82
2017
Q1
$72.9M Sell
866,406
-78,014
-8% -$6.25M 0.33% 76
2016
Q4
$69.5M Sell
944,420
-117,844
-11% -$8.78M 0.33% 79
2016
Q3
$85.3M Buy
1,062,264
+23,643
+2% +$1.89M 0.37% 67
2016
Q2
$81.8M Buy
1,038,621
+77,833
+8% +$5.86M 0.36% 67
2016
Q1
$69.2M Buy
960,788
+97,892
+11% +$7.41M 0.31% 83
2015
Q4
$72.7M Buy
862,896
+282,982
+49% +$23.5M 0.32% 81
2015
Q3
$48.5M Sell
579,914
-7,210
-1% -$609K 0.2% 144
2015
Q2
$49M Sell
587,124
-119,827
-17% -$9.13M 0.2% 147
2015
Q1
$51.4M Sell
706,951
-132,409
-16% -$9.43M 0.21% 136
2014
Q4
$57.9M Buy
839,360
+49,070
+6% +$3.31M 0.23% 129
2014
Q3
$51.3M Sell
790,290
-53,726
-6% -$3.4M 0.22% 139
2014
Q2
$52.5M Buy
844,016
+28,345
+3% +$1.69M 0.22% 137
2014
Q1
$48M Sell
815,671
-2,890,884
-78% -$161M 0.21% 137
2013
Q4
$189M Buy
3,706,555
+190,638
+5% +$9.55M 0.85% 16
2013
Q3
$177M Buy
3,515,917
+134,468
+4% +$7.04M 0.87% 19
2013
Q2
$166M Buy
+3,381,449
New +$184M 0.88% 22

Other funds holding LLY

Axa's LLY Position: Q1 2026 in Review

Axa reduced its Eli Lilly (LLY) stake by 35% in Q1 2026, selling an estimated $958K and leaving 1,780 shares worth $1.64M. The position accounts for 0.64% of the portfolio, ranked #21.

Axa first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $345M in Q2 2024. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Axa held 1,780 shares of Eli Lilly worth $1.64M as of Q1 2026.
  • Axa sold 945 Eli Lilly shares in Q1 2026, an estimated $958K.
  • Eli Lilly made up 0.64% of Axa's portfolio in Q1 2026, its #21 holding.
  • Axa first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Axa's Eli Lilly position peaked at $345M in Q2 2024.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Axa's 13F filing for Q1 2026, filed 15 May 2026.